• Using of Biosporin-Forte in complex treatment with antibiotics 
To content

Using of Biosporin-Forte in complex treatment with antibiotics 


HEALTH OF WOMAN. 2016.2(108):115–120; doi 10.15574/HW.2016.108.115 

Using of Biosporin-Forte in complex treatment with antibiotics 

Gopchuk O. M.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev 

AIM: To study an effectiveness of Biosporin-forte, comparing with synthetic antimycotic drugs, as prophylactics of post-antibiotic fungal complications, taking in attention increasing of general resistance of fungi to the modern antimycotics. 

Materials and Methods. A clinical-study-design was used. It included 90 fertile women, who went through antibiotic therapy to treat infections of reproductive system. All the patients were divided on three equal groups, one of which got synthetic antimycоtics (fluconazole) as a prophylactics of mycosis, one – tool oral forms of Lacto- and Bifidumbacteria, and the other one – got Biosporin-forte, which has direct influence on normal vaginal microflora and has high bioavailability. All the patients were completely examined: clinically and using laborathory methods. Both: before and after the treatment.

Results. The number of cultivated fungi, according to bacteriological data, was noticeably lower in group, who got Biosporin-forte as a prophylactic of mycosis, than Group 2 (6.7% and 26.7% accordingly). Also quantity of Lactobacilli of normal flora was higher in first Group (96.6% and 33.3%). According to this information it could be said, that Biosporin-forte is more effective as a prophylactics of post-antibiotic mycosis.

Conclusion. The using of medical forms of lactobacilli to prevent post-antibiotic vulvovaginitis – is perspective and effective method in modern gynecology. Moreover, fungi, which are resistant to classical synthetic antimycotics, still have high level of sensibility for antagonistic normal flora. So, using of Biosporin-forte is appropriate for treatment and prophylactics of fungal invasions.

Key words: Biosporin-forte, candidosis, antibiotics, prophylactic, non-albicans, vulvovaginitis.


1. Kirjavainen PV, Pautler S, Baroja ML et al. 2009. Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections. Clin Vaccine Immunol. 16:29–36. http://dx.doi.org/10.1128/CVI.00323-08; PMid:19020112 PMCid:PMC2620669

2. Ferrer J. 2014. Vaginal candidosis: epidemiological and etiological factors. Int J Gynecol Obstet. 71 (Supplement 1):21–27. http://dx.doi.org/10.1016/S0020-7292(00)00350-7

3. Kцhler GA, Assefa S, Reid G. 2012. Probiotic interference of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 with the opportunistic fungal pathogen Candida albicans. Infect Dis Obstet Gynecol. 17:63–64.

4. Badretdina FF, Ahmatgalyeva MA, Mynybaeva SA. 2007. Reabylytatcyonnie meropriyatiya pry bakteryal’nom vagynoze. Vestnyk vosstanovytel’noy medytcyni 2:62–64.

5. McMillan A, Dell M, Zellar MP et al. 2011. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces 86:58–64. http://dx.doi.org/10.1016/j.colsurfb.2011.03.016; PMid:21497071

6. Larsson PG, Brandsborg E, Forsum U et al. 2011. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect Dis. 10:123–126. http://dx.doi.org/10.1186/1471-2334-11-223

7. Zhukov SI, Tkachenko LV. 2003. Effective treatment regimen of acute and recurrent vulvovaginal candidiasis 16: 926.

8. Benyuk VA, Nikonyuk TP. 2008. Modern aspects of diagnosis and treatment of bacterial vaginosis. Medical aspects of women's health 5 (13): 22-24.

9. Martinez RCR, Franceschini SA, Patta MC et al. 2009. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Letters in Applied Microbiology 48(3):269–274. http://dx.doi.org/10.1111/j.1472-765X.2008.02477.x; PMid:19187507

10. Barrons R, Tassone D. 2008. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clinical Therapeutics 30(3):453–468. http://dx.doi.org/10.1016/j.clinthera.2008.03.013; PMid:18405785

11. Martinez RC, Franceschini SA, Patta MC et al. 2008. Analysis of vaginal lactobacilli from healthy and infected women. Appl Environ Microbiol. 74:4539–42. http://dx.doi.org/10.1128/AEM.00284-08; PMid:18502927 PMCid:PMC2493183